AIM ImmunoTech Inc.
AIM- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000946644
In the last 90 days, AIM ImmunoTech Inc. insiders filed 4 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $325.6K in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding AIM ImmunoTech Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 33 | 35 | +2 |
| Shares | 9.01M | 4.65M | −4.37M (−48.4%) |
| Value | $2.43M | $919.3K | −$1.51M (−62.2%) |
New holders (6)
Institutions that held AIM ImmunoTech Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Securities, LLC | 71,305 | $14.1K | 0.00% |
| Susquehanna International Group, LLP | 38,040 | $7.53K | 0.00% |
| Baader Bank INC | 13,389 | $2.37K | 0.00% |
| HB Wealth Management, LLC | 10,000 | $1.98K | 0.00% |
| Citigroup Inc | 864 | $171 | 0.00% |
| MAI Capital Management | 27 | $6 | 0.00% |
Sold out (4)
Institutions that held AIM ImmunoTech Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Armistice Capital, LLC | 4,330,000 | $1.17M |
| Bridgeway Capital Management, LLC | 11,000 | $2.97K |
| Northwestern Mutual Wealth Management Co | 600 | $162 |
| GWM Advisors LLC | 1 | $0 |